olaparib
merck,astrazeneca
['propel', 'magnitude', 'brca', 'crpc']
updated data from propel show rpfs benefits in 1st line mcrpc overall, greater magnitude in brcam patients. #esmo2022 
Professor of Medicine, Surgery, Pharmacology and Cancer Biology, Duke Cancer Institute, Durham NC